hypereosinophilic syndrome

Blood and tissue qualification

Record criterion thresholds, observation intervals and tissue routes without assuming that all frameworks agree.

1. Which issuing group and revision define the blood threshold, repeat-observation interval and tissue criteria being applied? provenance
2. Which dated blood counts or tissue observations satisfy each criterion, and were they obtained before eosinophil-suppressing treatment? measurement
3. How does this framework handle organ-threatening presentations before the usual observation interval is complete? boundary

Diagnostic and terminology alignment

Preserve the distinction between HES, isolated hypereosinophilia and framework-dependent overlap categories.

1. What evidence establishes eosinophil-attributable dysfunction rather than hypereosinophilia without attributable injury? definition
2. Does this framework include the observed organ-restricted or overlap presentation within HES? boundary
3. Which verified ICD-10 national modification, ICD-11 release or SNOMED CT edition maps to this syndrome and subtype? provenance

Secondary cause assessment

Track the completeness and limitations of investigations for alternative drivers.

1. Which medications, travel or residence exposures, infections and associated inflammatory or malignant disorders have been assessed? provenance
2. Which possible causes remain untested, and which were assessed with tests whose sensitivity or timing limits exclusion? boundary
3. Does the identified condition explain eosinophilia, organ injury, both or neither? definition

Molecular and cellular subtyping

Distinguish evidence of a myeloid process from an aberrant T-cell-associated process. [ASH clinical approach, 2022](https://ashpublications.org/hematology/article/2022/1/47/493536/Approach-to-the-patient-with-suspected)

1. What marrow morphology, cytogenetic or molecular evidence supports a myeloid neoplasm, including testing for FIP1L1::PDGFRA where indicated? measurement
2. What immunophenotypic, clonality and functional evidence supports a lymphocytic variant, and what remains inferential? measurement
3. Should the result revise the HES subtype and link to a separately classified underlying neoplasm? action

Organ-specific evidence map

Maintain separate assessments for cardiac, pulmonary, neurological, cutaneous, gastrointestinal and other involvement.

1. Which organs have symptoms, objective dysfunction, imaging abnormalities or pathological evidence, and on what dates? measurement
2. What supports eosinophilic causation in each organ, and which competing explanations have been considered? boundary

Urgent complication assessment

Capture suspected cardiac injury, thrombosis and severe respiratory or neurological involvement. [French guidelines, 2023](https://pmc.ncbi.nlm.nih.gov/articles/PMC10148979/)

1. Is there evidence of myocardial injury, intracardiac thrombus, embolism, respiratory compromise or acute neurological deficit? measurement
2. Which findings require urgent escalation under the applicable clinical pathway, and has clinician review occurred? action

Concordant and discordant trajectories

Make discrepancies between laboratory and clinical observations explicit.

1. How do absolute eosinophil counts, symptoms and organ-function measurements change across the same observation period? measurement
2. When these trajectories disagree, what evidence distinguishes ongoing disease, treatment effects, another condition and residual damage? boundary

Outcome definitions

Use explicit response and relapse definitions rather than assuming a universal staging system.

1. Which criteria define haematological response, clinical response, remission and relapse for this assessment? definition
2. What follow-up interval and observations support the current state, and what irreversible deficits remain? measurement

Population applicability

Contextualise epidemiology and prognosis by case definition and study population.

1. For any prevalence or incidence estimate, what were the population, geography, observation year, denominator and HES case definition? provenance
2. Does the evidence apply to this age group and causal subtype, or is applicability uncertain? boundary

Subtype and safety prerequisites

Record decision-relevant molecular findings, prior responses and infectious exposure assessment.

1. Which verified subtype, molecular result, organ manifestation or prior response supports the proposed intervention? action
2. Before systemic corticosteroids, how has relevant Strongyloides exposure or infection risk been assessed and addressed by the treating team? action
3. Which current guideline or jurisdiction-specific product indication supports eligibility, including age and subtype restrictions? provenance

Benefit, toxicity and reclassification

Link outcomes to exposure and identify reasons for renewed diagnostic review.

1. What changes in organ function, symptoms, eosinophil burden and treatment toxicity followed each intervention? measurement
2. What evidence would prompt clinician review of treatment failure, adherence, a missed driver or revised subtype? action
3. Which monitoring and reassessment decisions are documented, with responsible clinician and review date? action

Check these first

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these check these first hold for the sense of hypereosinophilic syndrome this model covers, and on what evidence? provenance

Kinds and varieties

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these kinds and varieties hold for the sense of hypereosinophilic syndrome this model covers, and on what evidence? provenance

Identifiers and schemes

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these identifiers and schemes hold for the sense of hypereosinophilic syndrome this model covers, and on what evidence? provenance

Standards and regulation

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these standards and regulation hold for the sense of hypereosinophilic syndrome this model covers, and on what evidence? provenance

Real-world use

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these real-world use hold for the sense of hypereosinophilic syndrome this model covers, and on what evidence? provenance

Typical measurements

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these typical measurements hold for the sense of hypereosinophilic syndrome this model covers, and on what evidence? provenance

Failure modes and hazards

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these failure modes and hazards hold for the sense of hypereosinophilic syndrome this model covers, and on what evidence? provenance

Regional variation

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these regional variation hold for the sense of hypereosinophilic syndrome this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these neighbouring kinds and how to tell them apart hold for the sense of hypereosinophilic syndrome this model covers, and on what evidence? provenance